6FK Stock Chart & Stats
€3.79
-€0.14(-4.17%)
At close: 4:00 PM EST
€3.79
-€0.14(-4.17%)
Day’s Range― - ―
52-Week Range€3.08 - €5.26
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€54.25M
Enterprise Value€909.94M
Total Cash (Recent Filing)€88.74M
Total Debt (Recent Filing)€4.34M
Price to Earnings (P/E)―
Beta0.25
Next Earnings
Oct 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.17
Shares Outstanding15,458,624
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Gentian Diagnostics ASA News
6FK FAQ
What was Gentian Diagnostics ASA’s price range in the past 12 months?
Gentian Diagnostics ASA lowest stock price was €3.08 and its highest was €5.26 in the past 12 months.
What is Gentian Diagnostics ASA’s market cap?
Gentian Diagnostics ASA’s market cap is €54.25M.
When is Gentian Diagnostics ASA’s upcoming earnings report date?
Gentian Diagnostics ASA’s upcoming earnings report date is Oct 20, 2026 which is in 101 days.
How were Gentian Diagnostics ASA’s earnings last quarter?
Gentian Diagnostics ASA released its earnings results on Jul 09, 2026. The company reported €0.026 earnings per share for the quarter, beating the consensus estimate of N/A by €0.026.
Is Gentian Diagnostics ASA overvalued?
According to Wall Street analysts Gentian Diagnostics ASA’s price is currently Overvalued.
Does Gentian Diagnostics ASA pay dividends?
Gentian Diagnostics ASA does not currently pay dividends.
What is Gentian Diagnostics ASA’s EPS estimate?
Gentian Diagnostics ASA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Gentian Diagnostics ASA have?
Gentian Diagnostics ASA has 15,458,624 shares outstanding.
What happened to Gentian Diagnostics ASA’s price movement after its last earnings report?
Gentian Diagnostics ASA reported an EPS of €0.026 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 8.766%.
Which hedge fund is a major shareholder of Gentian Diagnostics ASA?
Currently, no hedge funds are holding shares in DE:6FK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Gentian Diagnostics ASA
Gentian Diagnostics ASA develops, manufactures, and sells biochemical reagents for use in medical diagnostics and research in the United States, Asia, and Europe. It offers in-vitro diagnostic reagents for clinical chemistry analyzers, such as Gentian Calprotectin Immunoassay, a turbidimetric assay used for the measurement of circulating calprotectin in plasma and serum for detection and assessment of inflammation; Gentian Cystatin C Immunoassay test kit, a GFR marker for the diagnosis and therapeutic control of renal function and chronic kidney disease; Gentian Retinol-Binding Protein Immunoassay for detection of retinol-binding protein in human serum and plasma; and Canine CRP Immunoassay test kit, a particle-enhanced turbidimetric immunoassay for quantitative determination of canine C-reactive protein in dog plasma and serum. The company also develops faecal calprotectin immunoassay turbo that offers results of calprotectin concentration in stool supporting diagnosis of inflammatory bowel disease; and faecal pancreatic elastase immunoassay turbo, which allows analysis of pancreatic elastase in stool to aid in diagnosis of pancreatic exocrine insufficiency. Gentian Diagnostics ASA was founded in 2001 and is headquartered in Moss, Norway.